Anti-Inflammatory Biologics Market Size, Share & Industry Analysis, By Drug Class (Anti-Tumor Necrosis Factor (TNF), Interleukin Antagonists, Janus Kinase (JAK) Inhibitors, Others), By Application (Rheumatoid Arthritis, Psoriasis, and Others), By Route of Administration (Oral and Injection (Subcutaneous and Intravenous)), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and Regional Forecast, 2020-2027 (Includes COVID-19 Business Impact)

                                          
We have updated Anti-Inflammatory Biologics Market with respect to COVID-19 Business Impact.
Inquire before buying

This report focuses on the Anti-Inflammatory Biologics market and value at the global level, regional level, and company level. From a global perspective, this report represents the overall Anti-Inflammatory Biologics market size by analyzing historical data and future prospects. Regionally, this report focuses on several key regions: North America, Europe, Japan, China, Southeast Asia, India, Latin America, and South America.

Global Anti-Inflammatory Biologics Market: Segment Analysis


The research report includes specific segments by region (country), by Company, by Type, and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2019 to 2029. An in-depth analysis of the segments assists in identifying the different factors that will aid market growth.

Global Anti-Inflammatory Biologics Market: Regional Analysis

The research report includes a detailed study of regions of North America, Europe, Japan, China, Southeast Asia, India, Latin America, and South America. The report has been curated after observing and studying various factors that determine regional growth such as the economic, environmental, social, technological, and political status of the particular region. Researchers have studied the data of revenue, sales, and manufacturers of each mentioned region. This section analyses region-wise revenue and volume for the forecast period of 2019 to 2029.

Global Anti-Inflammatory Biologics Market: Competitive Landscape

This section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and sales by manufacturers during the forecast period of 2019 to 2029.
List of Companies Profiled

AbbVie to Account for the Leading Position
In terms of market revenue, AbbVie accounted for the leading position in the market. Higher sales of Humira, significant research investment, and established market presence are the factors attributable for the dominant share of AbbVie. In 2019, the company generated US$ 19.2 billion solely from the sale of Humira, which made the company a leader in the market. However, competition from the Adalimumab biosimilars is gradually eroding the market share of AbbVie. Moreover, the launch of biosimilars has also opened the window for other companies to gain considerable market positions.

LIST OF KEY COMPANIES PROFILED:

 	
AbbVie Inc.
 	
Merck & Co., Inc.
 	
Bristol-Myers Squibb Company
 	
Johnson & Johnson Services, Inc.
 	
Pfizer Inc.
 	
Novartis AG
 	
UCB S.A.
 	
Eli Lilly and Company
 	
Amgen Inc.
 	
Biogen
 	
Others

KEY INDUSTRY DEVELOPMENTS:

In October 2020, Gilead Sciences Ireland UC received marketing authorisation valid throughout the European Union for Jyseleca(Filgotinib) which is a medicine for treating adults with moderate to severe rheumatoid arthritis, a disease in which the immune system (the body’s natural defences) attacks healthy tissue to cause inflammation and pain in joints. Jyseleca is used alone or with another medicine, methotrexate, after treatment with one or more disease-modifying anti-rheumatic drugs (DMARDs) has not worked well enough or causes unacceptable side effects. DMARDs are medicines, such as methotrexate, that slow down the worsening of the disease.

December 2019 -UCB S.A. announced positive results from the phase 3 clinical study of Bimekizumab for the treatment of psoriasis.

December 2019 - Amgen received USFDA approval for Avsola, a biosimilar of infliximab. Avsola became the 4th infliximab biosimilar approved in the U.S.

August 2019 - In August 2019, AbbVie announced the launch of RINVOQ, janus kinase inhibitor for the treatment of rheumatoid arthritis.

October 2018 - Mylan announced the launch of Hulio, a biosimilar of adalimumab in Europe.

REPORT COVERAGE

The anti-inflammatory biologics market report offers a detailed analysis of the various factors affecting the market. These include growth drivers, restraints, opportunities, threats, and key developments. In addition to this, the report further helps in analyzing, segmenting, and defining the market based on different segments such as drug class, application, route of administration, and distribution channel. It also provides various key insights such as prevalence of psoriasis and rheumatoid arthritis for key countries, patent snapshot, pipeline analysis, new product launches, key mergers & acquisition, joint ventures, and others.
To gain extensive insights into the market, Request for Customization

Report Scope & Segmentation

By Drug Class

 	
Anti-Tumor Necrosis Factor (TNF)
 	
Interleukins Antagonists
 	
Janus Kinase (JAK) Inhibitors
 	
Others

By Application

 	
Rheumatoid Arthritis
 	
Psoriasis
 	
Others

By Route of Administration

 	
Oral
 	
Injection
 	
Intravenous
 	
Subcutaneous

By Distribution Channel

 	
Hospital Pharmacy
 	
Retail Pharmacy
 	
Online Pharmacy

By Geography

 	
North America (the U.S. and Canada)
 	
Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)
 	
Asia-Pacific (Japan, China, India, Australia, Southeast Asia, andRest of Asia- Pacific)
 	
Latin America (Brazil, Mexico, and Rest of Latin America)
 	
Middle East& Africa (South Africa, GCC and Rest of the Middle East & Africa)